Skip to main content
Skip to main content
MRNY logo

YieldMax MRNA Option Income Strategy ETF (MRNY)

$21.18 +$0.15 (+0.74%) |CouncilHOLD · 44 · C
Bottom line: HOLD — our Council read (44/100) and AI Score (44/100) broadly agree.
MCap: $133.06M| Vol: 272.5K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

YieldMax MRNA Option Income Strategy ETF (MRNY) trades at $21.18 with AI Score 44/100 (Grade C). The YieldMax MRNA Option Income Strategy ETF (MRNY) is an actively managed fund that generates weekly income by selling call options on Moderna (MRNA). Market cap: $133.06M, Sector: Financial services.

Price live · AI analysis from Mar 17, 2026
The YieldMax MRNA Option Income Strategy ETF (MRNY) is an actively managed fund that generates weekly income by selling call options on Moderna (MRNA). This strategy aims to provide income while participating in MRNA's share price appreciation.

Analyst Coverage for MRNY: MRNY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MRNY against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Council Score · Weighted Average of 3 Disciplines
HOLD 44/100 · C

MRNY: the 1 perspectives are evenly split.

How is this calculated? →
Council Score · 8 perspectives · See tabs for details →

YieldMax MRNA Option Income Strategy ETF (MRNY) Financial Services Profile

IPO Year2023

YieldMax MRNA Option Income Strategy ETF (MRNY) is an actively managed fund focused on generating weekly income by selling call options on Moderna (MRNA). It offers investors exposure to MRNA's potential upside while mitigating risk through option premiums, operating within the dynamic asset management sector.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 17, 2026

What Is the Investment Thesis for MRNY?

MRNY presents an investment opportunity for income-seeking investors who are comfortable with the risks associated with options trading and the biotechnology sector. The fund's primary value driver is its ability to generate consistent weekly income through the sale of call options on MRNA. The success of this strategy hinges on the fund's ability to accurately predict MRNA's price movements and manage the risk associated with potentially unlimited upside exposure for the option buyer. Key catalysts include continued volatility in MRNA's stock price, which can lead to higher option premiums. However, potential risks include significant declines in MRNA's stock price, which could erode the fund's net asset value, and changes in market conditions that could reduce the attractiveness of option-based income strategies. Investors should carefully consider these factors before investing in MRNY.

Based on FMP financials and quantitative analysis

MRNY Key Highlights

  • Market Cap of $133.06M indicates the fund's size and relative stability within the ETF market.
  • Beta of 0.25 suggests the fund is significantly less volatile than the broader market, offering a potentially lower-risk investment.
  • Actively managed strategy allows for adjustments based on market conditions and MRNA's price movements.
  • Focus on weekly income generation through option premiums provides a consistent stream of revenue for investors.
  • Exposure to MRNA's share price appreciation, albeit capped, offers potential upside participation.

Who Are MRNY's Competitors?

MRNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
CGV Conductor Global Equity Value ETF $15.71 +1.03% $137.87M 47
DSMC Distillate Small/Mid Cash Flow ETF $41.01 +0.03% $125.70M 47
HECO State Street Galaxy Hedged Digital Asset Ecosystem ETF $66.56 +2.46% $78.99M 47
IBIK iShares iBonds Oct 2034 Term TIPS ETF $25.19 +0.20% $83.39M 50
KEAT Keating Active ETF $31.48 -0.26% $122.09M 50
NXDT NexPoint Diversified Real Estate Trust $5.53 +3.08% $285.77M 73
GENB Generate Biomedicines, Inc. $17.03 -2.18% $2.18B 72
SII Sprott Inc. $118.11 +2.72% $3.05B 71

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MRNY's Key Strengths?

  • Weekly income generation.
  • Active management.
  • Exposure to MRNA's potential upside.
  • Relatively low beta.

What Are MRNY's Weaknesses?

  • Capped upside potential.
  • Dependence on MRNA's price movement.
  • Complexity of option strategies.
  • Potential for losses if MRNA's price declines significantly.

What Could Drive MRNY Stock Higher?

  • Continued volatility in MRNA's stock price, leading to higher option premiums.
  • Growing demand for income-generating investment strategies.
  • Potential new partnerships with brokerage firms to expand distribution.

What Are the Key Risks for MRNY?

  • Significant declines in MRNA's stock price, eroding the fund's net asset value.
  • Changes in market conditions that reduce the attractiveness of option-based income strategies.
  • Complexity of option strategies may deter some investors.
  • Dependence on the performance of a single stock (MRNA).

What Are the Growth Opportunities for MRNY?

  • Increased Adoption of Option Income Strategies: The growing popularity of option income strategies among retail and institutional investors presents a significant growth opportunity for MRNY. As investors seek alternative sources of yield in a low-interest-rate environment, the demand for ETFs like MRNY that generate income through option premiums is likely to increase. The market size for option income strategies is estimated to reach $500 billion by 2028, driven by the increasing sophistication of retail investors and the growing availability of option trading platforms. MRNY can capitalize on this trend by expanding its marketing efforts and educating investors about the benefits of its strategy.
  • Expansion into Other High-Volatility Stocks: MRNY's success with MRNA could be replicated with other high-volatility stocks in sectors such as technology and healthcare. By launching similar ETFs focused on companies with high option premiums, MRNY can diversify its product offerings and attract a wider range of investors. The market for single-stock option income ETFs is still relatively untapped, offering significant growth potential for innovative asset managers like YieldMax. The timeline for launching new ETFs is typically 6-12 months, allowing MRNY to quickly capitalize on emerging opportunities.
  • Strategic Partnerships with Brokerage Firms: Collaborating with brokerage firms to promote MRNY to their clients can significantly boost the fund's assets under management (AUM). By offering MRNY as a featured investment option on brokerage platforms, YieldMax can reach a large pool of potential investors who are actively seeking income-generating strategies. The market for ETF distribution through brokerage firms is highly competitive, but strategic partnerships can provide a significant competitive advantage. The timeline for establishing such partnerships is typically 3-6 months.
  • Development of Educational Resources: Creating educational resources about option income strategies can attract new investors to MRNY and enhance the fund's reputation as a thought leader in the ETF space. By providing clear and concise explanations of how the fund works, YieldMax can overcome investor skepticism and build trust. The market for financial education is growing rapidly, driven by the increasing self-direction of retail investors. MRNY can leverage this trend by creating webinars, blog posts, and other educational materials that demystify option trading.
  • International Expansion: Expanding the availability of MRNY to international investors can significantly increase the fund's AUM. By listing the ETF on foreign exchanges and marketing it to investors in countries with high demand for income-generating strategies, YieldMax can tap into new sources of capital. The market for international ETF investing is growing rapidly, driven by the increasing globalization of financial markets. The timeline for international expansion is typically 12-18 months, requiring careful planning and regulatory compliance.

What Opportunities Does MRNY Have?

  • Increased adoption of option income strategies.
  • Expansion into other high-volatility stocks.
  • Strategic partnerships with brokerage firms.
  • Development of educational resources.

What Threats Does MRNY Face?

  • Changes in market conditions.
  • Increased competition from other income-generating products.
  • Regulatory changes.
  • Significant declines in MRNA's stock price.

What Are MRNY's Competitive Advantages?

  • Active management expertise in option strategies.
  • Focus on a specific stock (MRNA) allows for specialized knowledge.
  • Weekly income generation provides a unique value proposition.
  • Established track record (if available).

What Does MRNY Do?

The YieldMax MRNA Option Income Strategy ETF (MRNY) is an actively managed exchange-traded fund designed to provide investors with weekly income. The fund achieves this by employing a strategy of selling call options or call spreads on shares of Moderna (MRNA). Launched with the goal of capturing option premiums, MRNY allows investors to participate in the potential share price appreciation of MRNA, albeit with a capped upside due to the nature of the options strategy. The fund's investment approach focuses on generating consistent income through option writing, making it an appealing option for income-seeking investors who have a view on the potential price movement of MRNA. The fund's performance is directly tied to the price fluctuations of MRNA and the premiums earned from the options contracts. As an actively managed ETF, MRNY's portfolio is continuously monitored and adjusted by its investment team to optimize income generation and manage risk. The fund is available to investors through various brokerage platforms, providing accessibility to a wide range of market participants.

What Products and Services Does MRNY Offer?

  • Sells call options or call spreads on MRNA shares.
  • Generates weekly income from option premiums.
  • Actively manages the fund's portfolio to optimize income and manage risk.
  • Provides investors with exposure to MRNA's potential share price appreciation.
  • Offers a capped upside potential due to the nature of the options strategy.
  • Distributes income to shareholders on a regular basis.

How Does MRNY Make Money?

  • Generates revenue by selling call options on MRNA.
  • Collects option premiums as income.
  • Manages expenses through fees charged to investors.

What Industry Does MRNY Operate In?

The asset management industry is characterized by a diverse range of investment strategies, including actively managed ETFs like MRNY. These funds compete with traditional mutual funds and passively managed index funds. The trend towards income-generating strategies is driven by investor demand for yield in a low-interest-rate environment. MRNY's focus on option-based income sets it apart from more traditional dividend-focused ETFs. The competitive landscape includes other option income ETFs and alternative investment products. The growth of the asset management industry is tied to overall market performance and investor sentiment.

Who Are MRNY's Key Customers?

  • Income-seeking investors.
  • Investors with a view on MRNA's price movement.
  • Investors looking for alternative sources of yield.
  • Retail investors.
  • Institutional investors.
AI Confidence: 81% Updated: Mar 17, 2026

MRNY Valuation & Market Position

Relative to its peer group, MRNY's quantitative score of 44/100 is roughly in line with the peer average of 48/100.

MRNY Financials

Bull Case vs Bear Case

Bull Case

  • Weekly income generation.
  • Active management.
  • Exposure to MRNA's potential upside.
  • Relatively low beta.

Bear Case

  • Capped upside potential.
  • Dependence on MRNA's price movement.
  • Complexity of option strategies.
  • Potential for losses if MRNA's price declines significantly.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026

MRNY Latest News

No recent news available for MRNY.

MRNY Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MRNY.

Price Targets

Wall Street price target analysis for MRNY.

MRNY MoonshotScore

44/100

What does this score mean?

The MoonshotScore rates MRNY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

MRNY Financial Services Stock FAQ

What does YieldMax MRNA Option Income Strategy ETF do?

The YieldMax MRNA Option Income Strategy ETF (MRNY) is an actively managed fund that seeks to generate weekly income by selling call options or call spreads on shares of Moderna (MRNA). This strategy allows investors to participate in the potential share price appreciation of MRNA, while also mitigating risk through the collection of option premiums. The fund's investment team actively monitors and adjusts the portfolio to optimize income generation and manage risk. MRNY is designed for income-seeking investors who are comfortable with the risks associated with options trading and the biotechnology sector.

What are the main risks for MRNY?

The main risks for MRNY include the potential for significant declines in MRNA's stock price, which could erode the fund's net asset value. Changes in market conditions that reduce the attractiveness of option-based income strategies also pose a risk. The complexity of option strategies may deter some investors, and the fund's dependence on the performance of a single stock (MRNA) makes it vulnerable to company-specific risks. Additionally, regulatory changes and increased competition from other income-generating products could negatively impact the fund's performance. Investors should carefully consider these risks before investing in MRNY.

How sensitive is MRNY to changes in MRNA's stock price volatility?

MRNY's performance is significantly influenced by the volatility of MRNA's stock price. Higher volatility generally leads to higher option premiums, which can boost the fund's income generation. However, extreme volatility can also increase the risk of the fund's options being exercised, potentially limiting its upside participation in MRNA's price appreciation. The fund's active management team continuously monitors MRNA's volatility and adjusts the option strategy accordingly to optimize income and manage risk. Investors should be aware that changes in MRNA's volatility can have a direct impact on MRNY's returns.

What is YieldMax MRNA Option Income Strategy ETF's expense ratio and how does it compare to similar funds?

The expense ratio for MRNY is Unknown. The expense ratio represents the annual cost of operating the fund, expressed as a percentage of the fund's average net assets. A lower expense ratio is generally more favorable for investors, as it means more of the fund's returns are passed on to shareholders. When evaluating MRNY, investors should compare its expense ratio to those of similar option income ETFs to assess its cost-effectiveness. However, it's important to consider that a higher expense ratio may be justified if the fund's active management team consistently delivers superior performance.

What are the key factors to evaluate for MRNY?

YieldMax MRNA Option Income Strategy ETF (MRNY) holds an AI score of 44/100 (low). Not financial advice.

How frequently does MRNY data refresh on this page?

MRNY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven MRNY's recent stock price performance?

YieldMax MRNA Option Income Strategy ETF (MRNY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Weekly income generation. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MRNY overvalued or undervalued right now?

Valuing YieldMax MRNA Option Income Strategy ETF (MRNY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • AI analysis pending for MRNY, limiting the depth of available insights.
  • Financial data is based on available information and may be subject to change.
Data Sources

Popular Stocks